MX2022009270A - Un inhibidor de cd36 para usarse en una terapia combinada para el tratamiento de cáncer y la metástasis del cáncer. - Google Patents

Un inhibidor de cd36 para usarse en una terapia combinada para el tratamiento de cáncer y la metástasis del cáncer.

Info

Publication number
MX2022009270A
MX2022009270A MX2022009270A MX2022009270A MX2022009270A MX 2022009270 A MX2022009270 A MX 2022009270A MX 2022009270 A MX2022009270 A MX 2022009270A MX 2022009270 A MX2022009270 A MX 2022009270A MX 2022009270 A MX2022009270 A MX 2022009270A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
combination therapy
metastasis
cancer metastasis
Prior art date
Application number
MX2022009270A
Other languages
English (en)
Spanish (es)
Inventor
Benitah Salvador Aznar
Pier Giorgio Amendola
Valerie Vanhooren
Frias Sanchez Mercè De
Armisen Beatriz Morancho
Original Assignee
Ona Therapeutics S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ona Therapeutics S L filed Critical Ona Therapeutics S L
Publication of MX2022009270A publication Critical patent/MX2022009270A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
MX2022009270A 2020-01-30 2021-01-29 Un inhibidor de cd36 para usarse en una terapia combinada para el tratamiento de cáncer y la metástasis del cáncer. MX2022009270A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062967875P 2020-01-30 2020-01-30
EP20382054 2020-01-30
PCT/IB2021/050747 WO2021152548A1 (en) 2020-01-30 2021-01-29 Combination therapy for treatment of cancer and cancer metastasis

Publications (1)

Publication Number Publication Date
MX2022009270A true MX2022009270A (es) 2022-10-27

Family

ID=74347467

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009270A MX2022009270A (es) 2020-01-30 2021-01-29 Un inhibidor de cd36 para usarse en una terapia combinada para el tratamiento de cáncer y la metástasis del cáncer.

Country Status (11)

Country Link
US (1) US20230086099A1 (cg-RX-API-DMAC10.html)
EP (1) EP4097130A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023512276A (cg-RX-API-DMAC10.html)
KR (1) KR20220133996A (cg-RX-API-DMAC10.html)
CN (1) CN115397859A (cg-RX-API-DMAC10.html)
AU (1) AU2021213969A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022014962A2 (cg-RX-API-DMAC10.html)
CA (1) CA3168923A1 (cg-RX-API-DMAC10.html)
IL (1) IL295093A (cg-RX-API-DMAC10.html)
MX (1) MX2022009270A (cg-RX-API-DMAC10.html)
WO (1) WO2021152548A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021176424A1 (en) 2020-03-06 2021-09-10 Ona Therapeutics, S.L. Anti-cd36 antibodies and their use to treat cancer
CA3226281A1 (en) * 2021-07-30 2023-02-02 ONA Therapeutics S.L. Anti-cd36 antibodies and their use to treat cancer
WO2023172863A1 (en) * 2022-03-07 2023-09-14 Elixiron Immunotherapeutics (hong Kong) Limited Anti-cd36 antibodies and uses thereof
CN117462687A (zh) * 2022-07-20 2024-01-30 清华大学 一种用于制备预防或治疗骨转移癌药物的组合物及其应用
CN118697878B (zh) * 2024-05-28 2025-02-11 广东省人民医院 Cd36作为抑制肺癌脑膜转移的分子标志物和治疗靶点的应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
MXPA02001878A (es) 1999-08-23 2003-08-20 Dana Farber Cancer Inst Inc Moleculas b7-4 novedosas y usos de las mismas.
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
CA3016482A1 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
WO2003032813A2 (en) 2001-10-18 2003-04-24 Genentech Inc. Methods for the treatment of carcinoma
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
CA3175360C (en) 2013-05-31 2024-05-28 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
CA2971734C (en) 2014-12-22 2025-11-18 Pd-1 Acquisition Group, Llc Anti-pd-1 antibodies
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
HRP20201334T1 (hr) 2015-04-17 2020-11-27 Bristol-Myers Squibb Company Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
WO2016197367A1 (en) 2015-06-11 2016-12-15 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
PE20231958A1 (es) 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2017024515A1 (en) 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
MX392711B (es) 2015-08-11 2025-03-24 Wuxi Biologics Ireland Ltd Anticuerpos anti-pd-1 novedosos.
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
JP6869987B2 (ja) 2015-09-01 2021-05-12 アジェナス インコーポレイテッド 抗ｐｄ−１抗体及びその使用方法
EP3650468A1 (en) 2015-09-29 2020-05-13 Fundació Institut de Recerca Biomèdica (IRB Barcelona) Targeting metastasis stem cells through a fatty acid receptor (cd36)
CN108367069B (zh) 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
JP7082051B2 (ja) 2016-01-11 2022-06-07 アルモ・バイオサイエンシーズ・インコーポレイテッド 抗原特異的ｃｄ８＋ｔ細胞の産生におけるインターロイキン－１０及びその使用方法
EP3402255B1 (en) 2016-02-02 2021-03-31 Huawei Technologies Co., Ltd. Emission power verification method, user equipment, and base station
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
EP3618829B1 (en) * 2017-05-05 2023-06-07 Arcus Biosciences, Inc. Quinazoline-pyridine derivatives for the treatment of cancer-related disorders
CN111315398A (zh) * 2017-11-10 2020-06-19 阿尔莫生物科技股份有限公司 白介素-10与免疫检查点途径抑制剂的组合的组合物和使用方法
GB201802307D0 (en) * 2018-02-13 2018-03-28 Vib Vzw CD36 antagonists for use in melanoma treatment
WO2019173682A1 (en) * 2018-03-09 2019-09-12 Arcus Biosciences, Inc. Parenterally administered immune enhancing drugs
CA3109563A1 (en) * 2018-09-14 2020-03-19 Universite De Lausanne Methods for modulating regulatory t cells and inhibiting tumor growth

Also Published As

Publication number Publication date
IL295093A (en) 2022-09-01
WO2021152548A1 (en) 2021-08-05
BR112022014962A2 (pt) 2022-09-20
CA3168923A1 (en) 2021-08-05
EP4097130A1 (en) 2022-12-07
CN115397859A (zh) 2022-11-25
JP2023512276A (ja) 2023-03-24
US20230086099A1 (en) 2023-03-23
AU2021213969A1 (en) 2022-09-01
KR20220133996A (ko) 2022-10-05

Similar Documents

Publication Publication Date Title
MX2022014104A (es) Inhibidores de atr para el tratamiento del cancer.
EA201890961A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
MA40437A (fr) Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux
BR112022014962A2 (pt) Terapia de combinação para tratamento de câncer e metástase de câncer
AU201814589S (en) Ultrasound therapeutic treatment handpiece
MX2020008906A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso de estos.
MX2022008868A (es) Tratamiento del cancer con tg02.
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
CL2018000943A1 (es) Terapia de combinación para tratar tumores malignos
TN2013000508A1 (en) Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
MX2020009773A (es) Terapia de combinacion.
MX2022011050A (es) Anticuerpos anti-cd36 y su uso para tratar cancer.
EA201890968A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
MX2023000549A (es) Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr.
MX2019013862A (es) Terapia de combinacion.
MX2023005234A (es) Terapia de combinacion de agente anti-cd19 y agente de direccionamiento a celulas b para el tratamiento de neoplasias malignas de celulas b.
MX2020001727A (es) Terapia de combinacion.
AU201814587S (en) Ultrasound therapeutic treatment cart
MX2019002108A (es) Terapia de combinacion con inhibidores de glutaminasa.
MX2024006678A (es) Inhibidor de cdk4 para el tratamiento del cancer.
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
NI201700024A (es) Tratamientos médicos a base de anamorelina
MX2023006542A (es) Inhibidores de la vía cinasa jano 1 (jak1) para el tratamiento del vitiligo.
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.